Showing results (61-70 of 81) with videos related to

Sort By:
Pageof 9
Targeted Oncology|October 18, 2021
A Real-World Study of Patients with Advanced Non-squamous Non-small Cell Lung Cancer with EGFR Exon 20 Insertion: Clinical Characteristics and OutcomesChristos Chouaid, Thomas Filleron, Didier Debieuvre, et al.
Lung Cancer (Amsterdam, Netherlands)|June 4, 2015
Renal insufficiency is the leading cause of double maintenance (bevacizumab and pemetrexed) discontinuation for toxicity to advanced non-small cell lung cancer in real world settingMarion Sassier, Audrey Emmanuelle Dugué, Bénédicte Clarisse, et al.
Lung Cancer (Amsterdam, Netherlands)|January 20, 2022
Tailoring maintenance chemotherapy upon response to induction chemotherapy as compared with pemetrexed continuation maintenance in advanced non-squamous NSCLC patients: Results of the IFCT-GFPC-1101 multicenter randomized phase III trialPierre-Jean Souquet, Clarisse Audigier-Valette, Olivier Molinier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2004
Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapyNasser Hanna, Frances A Shepherd, Frank V Fossella, et al.
Annals of Translational Medicine|August 5, 2021
Detection of ALK fusion transcripts in plasma of non-small cell lung cancer patients using a novel RT-PCR based assaySimon Heeke, Jonathan Benzaquen, Audrey Vallee, et al.
British Journal of Clinical Pharmacology|September 25, 2016
Utility of serum anti-cetuximab immunoglobulin E levels to identify patients at a high risk of severe hypersensitivity reaction to cetuximabBenoît Dupont, Delphine Mariotte, Audrey E Dugué, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 17, 2023
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non-Small-Cell Lung Cancer Previously Treated With ChemotherapyNasser Hanna, Frances A Shepherd, Frank V Fossella, et al.
Lancet (London, England)|November 26, 2008
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trialEdward S Kim, Vera Hirsh, Tony Mok, et al.
The Lancet. Oncology|September 5, 2020
Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trialNathalie Baize, Isabelle Monnet, Laurent Greillier, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 28, 2021
Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1-Positive Advanced NSCLCRoy S Herbst, Edward B Garon, Dong-Wan Kim, et al.
Pageof 9